Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03498716 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,199
- Enrollment target
NCT03498716 is a Phase 3 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 2,199 participants.
The verdict
NCT03498716, a Phase 3 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,199 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer)
Interventions
- DRUG Cyclophosphamide
- DRUG Atezolizumab
- DRUG Paclitaxel
- DRUG Dose-dense Doxorubicin or dose-dense Epirubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,199 participants |
| Start Date | 2018-08-02 |
| Est. Completion | 2023-08-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03498716
The ClinicalTrials.gov registry entry for NCT03498716 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT03498716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03498716 about?
NCT03498716 is a clinical study titled "A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer". This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or ep...
What is the current status of trial NCT03498716?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,199 participants. The study started on 2018-08-02. Estimated completion is 2023-08-14.
What interventions are being tested in trial NCT03498716?
The interventions under investigation include: Cyclophosphamide (DRUG), Atezolizumab (DRUG), Paclitaxel (DRUG), Dose-dense Doxorubicin or dose-dense Epirubicin (DRUG).
Who is sponsoring clinical trial NCT03498716?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.